Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pertussis vaccine-Public Health England-Meningococcal Group C infection-Pertussis
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The drug entry "pertussis vaccine-Public Health England-Meningococcal Group C infection-Pertussis" refers to the concomitant administration of a Meningococcal Group C (MenC) conjugate vaccine and an acellular pertussis-containing booster vaccine as evaluated in the "Multiboost" Phase III/IV clinical trial (NCT01423825). Conducted by Public Health England, this study assessed the immunogenicity and safety of co-administering these vaccines in adolescents aged 13-17 years to streamline the UK routine immunization schedule. The regimen involves the simultaneous but separate injection of a MenC vaccine (such as Meningitec, NeisVac-C, or Menitorix) and a pertussis-containing booster (such as Repevax or IPV-Boostrix), the latter of which also provides protection against diphtheria, tetanus, and poliomyelitis. The study aimed to determine if the immune response to each component remains robust when given together compared to separate administration.
- Brand names
- MeningitecNeisVac-CMenitorixRepevaxIPV-Boostrix
- Other names
- Concomitant MenC and Pertussis Booster in AdolescentsMeningococcal Group C vaccine + Pertussis vaccine
02
Targets
PRN (Pertactin)Fimbrial antigen type 3Neisseria meningitidis group C capsular polysaccharideFHA (Filamentous hemagglutinin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on pertussis vaccine-Public Health England-Meningococcal Group C infection-Pertussis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pertussis vaccine-Public Health England-Meningococcal Group C infection-Pertussis.